Analysts have clear opinions on AXSM.

There are 9 analysts on the Wall offering 12 month price targets for Axsome Therapeutics in the last 3 months. The average price target is $140.25 with a high forecast of $200.00 and a low forecast of $95.00. The average price target represents a 58.06% increase from the last price of $88.73.
Axsome Therapeutics, Inc. (AXSM) is followed by 9 analysts on the street.

Ram Selvaraju from H.C. Wainwright rates it a Buy with a target of $200.00.

Similarly, 7 days ago Matthew Kaplan of Ladenburg Thalmann & Co. Reiterated a Buy with a target of $165.00.

The consensus on the street is Strong Buy.

What does Axsome Therapeutics, Inc.(AXSM) do ?
Axsome Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies for the management of central nervous system disorders. Its product candidates include AXS-02 and AXS-06 which are developing for multiple indications. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics, Inc. (AXSM) Insider Trades

Multiple company employees have indulged in significant insider trading. Axsome Therapeutics, Inc. disclosed the following in a document filed with the US Securities and Exchange Commission (SEC):

Dir, Coleman Mark : P – Purchase(+$374,280) of AXSM in the trading session of 2019-06-25.

CFO Pizzie Nick : P – Purchase(+$39,936) of AXSM in the trading session of 2019-06-11.

Dir Saad Mark E : P – Purchase(+$78,155) of Axsome Therapeutics, Inc. in the trading session of 2019-05-23.

Looking for stocks just like AXSM?

Based on Wall Street analyst research, several stocks are similar to AXSM
They are:
– ITCI [Info can be found here: ]
– LLY [Info can be found here: ]
– FLXN [Info can be found here: ]